BCR and B-cell chronic lymphocytic leukemia: A previous study reported higher sensitivity of U-CLL to several CHEK1 inhibitors and hypothesized that this was due to off-target effects of the CHEK1 inhibitors towards components of the BCR-pathway, which are known to have differential dependence between U-CLL and M-CLL [16].